Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atumelnant PK and safety in Japanese and Caucasian healthy volunteers
NCT07221084Phase 1Completed
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Oct 2025
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of atumelnant in congenital adrenal hyperplasia (CAH) and Cushing's disease (CD), sponsored by Crinetics Pharmaceuticals. Primary endpoints: Maximum observed plasma concentration at 30 days, Time to maximum observed plasma concentration at 30 days and 1 more. Started Oct 2025; status: completed.
02
Drugs
atumelnant
03
Conditions
congenital adrenal hyperplasia (CAH)Cushing's disease (CD)
Beyond the preview
Go deeper on NCT07221084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221084.